Compare NPCE & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NPCE | TECX |
|---|---|---|
| Founded | 1997 | 2019 |
| Country | United States | United States |
| Employees | N/A | 60 |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.6M | 549.5M |
| IPO Year | 2021 | N/A |
| Metric | NPCE | TECX |
|---|---|---|
| Price | $16.09 | $32.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $18.33 | ★ $75.20 |
| AVG Volume (30 Days) | 172.6K | ★ 184.8K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,986,000.00 | N/A |
| Revenue This Year | $0.90 | N/A |
| Revenue Next Year | $24.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.13 | N/A |
| 52 Week Low | $7.56 | $14.39 |
| 52 Week High | $19.60 | $39.53 |
| Indicator | NPCE | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 48.88 |
| Support Level | $15.42 | $27.31 |
| Resistance Level | $17.49 | $35.99 |
| Average True Range (ATR) | 0.88 | 2.76 |
| MACD | -0.06 | -0.47 |
| Stochastic Oscillator | 22.09 | 21.07 |
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.